FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the field of biochemistry, in particular to clostridial neurotoxins with a modified persistence. Claimed is a polypeptide, containing HC-domain, the first and, at least, one additional LC-domain with amino acid sequences, at least, 90% identical to the respective sequences of a neurotoxic component of botulotoxin of a serotype A, B, C1, D, E, F or G. Also claimed are nucleic acid, an expression vector and a host cell, intended for the expression of the said polypeptide. Also claimed are a method of obtaining and application of the said polypeptide, including as a component of a pharmaceutical composition, for treatment of a condition, associated with hyperactive cholinergic innervations of a muscle or a exocrine gland, and for cosmetic procedures, associated with wrinkles.
EFFECT: invention makes it possible to controllably vary a period of activity of clostridial neurotoxins.
12 cl, 1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STABILIZED NON-PROTEIN COMPOSITIONS OF CLOSTRIDIAL TOXIN | 2017 |
|
RU2762607C2 |
| METHOD OF PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDE | 2012 |
|
RU2673910C2 |
| Liquid composition containing botulinum toxin and a stabilizing agent, and a method for its preparation | 2017 |
|
RU2748653C2 |
| CATIONIC NEUROTOXINS | 2015 |
|
RU2733493C2 |
| METHODS FOR PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDES | 2018 |
|
RU2719164C1 |
| ENGINEERED BOTULINUM NEUROTOXIN | 2016 |
|
RU2746736C2 |
| SORTASE-LABELED CLOSTRIDIA NEUROTOXINS | 2020 |
|
RU2801120C2 |
| METHODS OF TREATING CHRONIC NEUROGENIC INFLAMMATION BY MODIFIED CLOSTRIDIAL TOXIN | 2010 |
|
RU2568844C2 |
| THERAPEUTIC FUSION PROTEINS | 2012 |
|
RU2651492C2 |
| DEVICES AND METHOD TO PRODUCE HIGHLY CLEANED NEUROTOXINS | 2010 |
|
RU2571212C2 |
